Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Positive clinical results reported for MDX-22 in AML patients

Dec. 12, 1996

Positive IDEC-C2B8 phase III trial results announced

Dec. 11, 1996

Medarex bispecific antibody enters phase II in colon cancer patients

Dec. 9, 1996

Sandoz claims MAbs against Lewis group antigens for therapeutic use

Nov. 25, 1996

IDEC to present final pivotal data on IDEC-C2B8

Nov. 22, 1996

NCI sponsors clinical trials with Therion's prostate cancer vaccine

Nov. 22, 1996

First filing for Imutec's Virulizin

Nov. 21, 1996

Final phase II data presented for Biomira's therapeutic cancer vaccine

Nov. 15, 1996

Ovarian cancer vaccine enters pivotal trials in Europe

Nov. 8, 1996

Apoptosis-inducing MAb from Chugai

Nov. 8, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...